ProCE Banner Activity

Phase Ib/II Trial of Lurbinectedin Plus Irinotecan in Patients With Advanced Solid Tumors

Slideset Download
Conference Coverage
Combined treatment with lurbinectedin and irinotecan yields promising early antitumor activity in small-cell lung cancer, with an ORR of 69.2% in 13 evaluable patients.

Released: June 04, 2020

Expiration: June 03, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Jazz Pharmaceuticals, Inc.

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono